Sarepta Therapeutics, Inc.

As of August 12, 2025, Sarepta Therapeutics, Inc. is in a mildly bearish trend, with mixed technical indicators showing underperformance of -84.77% year-to-date compared to the S&P 500's 12.22% return.

As of May 6, 2025, Sarepta Therapeutics, Inc. is considered risky and overvalued, with concerning valuation metrics and a year-to-date stock performance decline of 84.77%, significantly underperforming the S&P 500's 12.22% gain.

As of May 6, 2025, Sarepta Therapeutics, Inc. is considered risky and overvalued due to negative financial metrics, including a P/E ratio and poor stock performance, contrasting unfavorably with peers like Royalty Pharma.

As of February 12, 2025, the technical trend has shifted to a bearish stance, supported by negative MACD readings, bearish Bollinger Bands, and moving averages, despite a bullish weekly RSI.

As of March 2022, the management team of Sarepta Therapeutics, Inc. includes Dr. M. Kathleen Behrens (Independent Chairwoman), Mr. Douglas Ingram (President and CEO), and several Independent Directors: Mr. Richard Barry, Dr. Mary Gray, Dr. John Martin, Dr. Claude Nicaise, and Dr. Hans Wigzell. They are responsible for guiding the company's strategic direction.

Sarepta Therapeutics, Inc. is a biopharmaceutical company specializing in RNA-targeted therapeutics for rare neuromuscular diseases, particularly Duchenne muscular dystrophy. As of March 2025, it reported net sales of $745 million and a net loss of $448 million, with a market cap of approximately $2.12 billion.

As of Jun 18, Sarepta Therapeutics, Inc. has a market capitalization of $2.12 billion, with net sales of $2.23 billion and a net profit of -$248.39 million over the last four quarters.